Literature DB >> 24738133

Endometrial hepatoid adenocarcinoma: a rare cause of elevated serum α-fetoprotein.

Qiong Yan Wu, Xiao Yun Wan, Xing Xie, Bing Jian Lu.   

Abstract

Hepatoid adenocarcinoma is a rare and unusual tumor in the female genital tract. Hepatoid adenocarcinoma resembles hepatocellular carcinoma morphologically but develops in extrahepatic organs, and usually demonstrates foci of adenocarcinoma of the primary organ. Tumor cells often stain positive for anti-α-fetoprotein antibody, and may be associated with elevated serum α-fetoprotein, which may be useful as a tumor marker to guide treatment. There is little reliable information to guide clinical management of these unusual tumors and prognosis is poor despite multi-modal treatment. This report describes the diagnosis and treatment of this tumor in a postmenopausal woman.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24738133     DOI: 10.1111/jog.12237

Source DB:  PubMed          Journal:  J Obstet Gynaecol Res        ISSN: 1341-8076            Impact factor:   1.730


  3 in total

1.  Disseminated Primary Uterine Hepatoid Adenocarcinoma with α-Fetoprotein Production Demonstrated on 18F-FDG PET/CT.

Authors:  Danijela Dejanovic; Marie Boennelycke; Annemarie Gjelstrup Amtoft; Charlotte Birk Christensen; Victoria Wetterstroem; Annika Loft; Trine Jakobi Noettrup
Journal:  Diagnostics (Basel)       Date:  2022-06-12

2.  α-Fetoprotein-Producing Endometrial Carcinoma Is Associated With Fetal Gut-Like and/or Hepatoid Morphology, Lymphovascular Infiltration, TP53 Abnormalities, and Poor Prognosis: Five Cases and Literature Review.

Authors:  Tomoyuki Otani; Kosuke Murakami; Naoki Shiraishi; Man Hagiyama; Takao Satou; Mitsuru Matsuki; Noriomi Matsumura; Akihiko Ito
Journal:  Front Med (Lausanne)       Date:  2021-12-15

3.  Extra-Hepatic Hepatoid Carcinomas in Female Reproductive System: Three Case-Reports with a Literature Review.

Authors:  Yao Liu; Ruiqi Zhou; Shourong Wang; Guiyu Zhang
Journal:  Cancer Manag Res       Date:  2021-02-17       Impact factor: 3.989

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.